Tomahawk, WI 03/25/2014 (Basicsmedia) – Pfizer Inc. (NYSE:PFE) today made public the results of oral treatment Psoriasis Trial (OPT) compare (A3921080), a Phase 3 study of Xeljanz (tofacitinib). It is first of kind of oral Janus kinase (JAK) inhibitor treatment and it safety and efficacy are investigated so after successful trail it can be given to adults. This will be used for the treatment of chronic plaque psoriasis which can be normal to alarming level in adults. It was one of the largest clinical trials for the Psoriasis which was expanded over 36 countries and included 3600 patients.

Announcing the result Herve Bachelez, of the Sorbonne Paris Cite Universite Paris Diderot, Department of Dermatology, APHP Hopital Saint-Louis, France said the result showed the non-inferiority of an oral small molecule, tofacitinib, vs an injected biologic agent, Enbrel, in psoriasis.

The study of efficacy and safety of tofacitinib was compared to Enbrel and results were noted. It was all done under supervision. The doses approved were 5mg and 10mg twice daily (BID) for tofacitinib and for Enbrel it was 50mg twice weekly (BIW).

Results Compared:

The outcome of the oral treatment Psoriasis Trial showed that tofacitinib 10mg BID was equivalent to Enbrel 50mg BIW as studied differently by PASI (Psoriasis Area and Severity Index) 75 response and PGA (Physician’s Global Assessment) response.

The 63.6% the patients, who took tofacitinib 10mg BID, achieved a PASI75 response at week 12 and for tofacitinib 5mg BID it was 39.5%. The result was 58.8% for Enbrel 50mg BIW.While in the study of PGA the percentage of patients  that achieved “clear” or “almost clear” in week 12 were 68.2% for tofacitinib 10mg BID and 47.1% for tofacitinib 5mg BID, 66.3% for the Enbrel 50mg.

Precaution to be taken

Tofacitinib (Xeljanz) safety and effectiveness is not clear People with Hepatitis B or C.

People with severe liver problem can’t take this medicine.

It’s safety and effectiveness among children is not decided yet.

There are many other areas when this Xeljanz can’t be prescribed.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.